Related Experiment Video
Updated: Jul 12, 2026
Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
Published on: April 3, 2026
Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future
Carol R Bradford1, Sreeram M P2, Karthik N Rao3
1Department of Otolaryngology-Head and Neck Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Background:
Head and neck squamous cell carcinoma (HNSCC) is frequently diagnosed at advanced stages and has historically been associated with poor outcomes. Immune checkpoint inhibition has transformed the therapeutic landscape, offering durable responses in recurrent, metastatic, and locally advanced disease.
Methods:
This review summarizes pivotal clinical trials evaluating immunotherapeutic strategies in HNSCC, including PD-1/PD-L1 inhibitors, combination regimens, and emerging modalities across recurrent/metastatic and curative-intent settings, with attention to efficacy, safety, and biomarkers.
Results:
Phase III trials have established pembrolizumab and nivolumab as standards of care in recurrent or metastatic HNSCC, demonstrating improved overall survival and favorable toxicity profiles. Recent studies support earlier integration of immunotherapy, including neoadjuvant and adjuvant approaches, with meaningful gains in event-free and disease-free survival.
Conclusions:
Immunotherapy is reshaping the management of HNSCC. Ongoing trials, biomarker refinement, and novel strategies are expected to further expand benefit and personalize treatment.
Insights
Immune checkpoint inhibitors like PD-1/PD-L1 therapies are improving outcomes for head and neck squamous cell carcinoma (HNSCC). Earlier integration of immunotherapy shows promise for better survival rates in HNSCC patients.
Area of Science:
- Oncology
- Immunotherapy
- Head and Neck Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) often presents at advanced stages with poor prognoses.
- Immune checkpoint inhibitors have significantly improved treatment outcomes for recurrent, metastatic, and locally advanced HNSCC.
Purpose of the Study:
- To review pivotal clinical trials of immunotherapeutic strategies in HNSCC.
- To analyze efficacy, safety, and biomarkers of immunotherapy in HNSCC management.
Main Methods:
- Systematic review of Phase III clinical trials evaluating PD-1/PD-L1 inhibitors and combination regimens.
- Analysis of immunotherapy in both recurrent/metastatic and curative-intent settings.
Main Results:
- Pembrolizumab and nivolumab are established standards of care for recurrent/metastatic HNSCC, improving overall survival.
- Neoadjuvant and adjuvant immunotherapy approaches demonstrate significant gains in event-free and disease-free survival.
Conclusions:
- Immunotherapy is revolutionizing HNSCC treatment paradigms.
- Future directions include ongoing trials, biomarker development, and personalized treatment strategies for HNSCC.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...